CALIFORNIA | LOCAL
March 9, 1993 |
What is wrong with this picture: An American industry universally acclaimed as the most competitive and technologically advanced in the world is nonetheless in deep trouble. Layoffs and mass firings are rampant. The stock market value of the industry plummets by a third in one year, as more than $100 billion of capital flees to more promising uses.
March 14, 2006 |
Client confidentiality prevents Andrew Schirmer from revealing specifics, but it's easy to believe his claim that his job has been especially challenging lately. Schirmer is trying to devise a new ad campaign for Viagra, Pfizer Inc.'s erectile dysfunction drug, after racy spots for impotency pills helped fuel the public's ire over drug commercials.
December 7, 2003 |
"Subject No. 4" died at 1:44 a.m. on June 14, 1999, in the immense federal research clinic of the National Institutes of Health. The cause of death was clear: a complication from an experimental treatment for kidney inflammation using a drug made by a German company, Schering AG. Among the first to be notified was Dr. Stephen I. Katz, the senior NIH official whose institute conducted the study. Unbeknown to the participants, Katz also was a paid consultant to Schering AG.
December 14, 2009 |
When your doctor writes you a prescription, that's just between you, your doctor and maybe your health insurance company -- right? Wrong. As things stand now, the pharmaceutical companies that make those prescription drugs are looking over the doctor's shoulder to keep track of how many prescriptions for each drug the physician is writing. By obtaining data from pharmacies and health insurers, the drug companies learn the prescribing habits of thousands of doctors. That information has become not just a powerful sales and marketing tool for the pharmaceutical industry but also a source of growing concern among some elected officials, healthcare advocates and legal authorities.
October 28, 2005 |
CALIFORNIANS ARE in danger of being rolled by the big drug companies on Nov. 8. On the face of it, the two propositions on the ballot dealing with prescription drug discounts might seem to be different ways to achieve the same goal: lower prices for vulnerable Californians. But in fact, Proposition 78 is a decoy created by the drug companies to draw votes from Proposition 79, which actually would lower prices. Let's look more closely at the two propositions.
December 22, 2006 |
THE PHARMACEUTICAL industry is getting bad press. Recent books by Marcia Angell, the former editor of the New England Journal of Medicine, and Jerome Kassirer, another former editor of the journal, have harshly condemned the industry for recklessness, insensitivity and all-consuming greed. They gain sales by spicing up their titles with inflammatory phrases about "deception," "complicity" and how drug companies "endanger your health." I take a different approach.
January 19, 1996 |
A group of pharmaceutical manufacturers has tentatively agreed to pay nearly $600 million to settle a lawsuit brought by 40,000 independent pharmacies that accused drug makers of a widespread pricing conspiracy, lawyers and others involved in the case said Thursday.
August 17, 2000 |
A Boston technology firm is surreptitiously tracking computer users across the Internet on behalf of pharmaceutical companies, a practice that demonstrates the limits of a recent agreement to protect the privacy of Web surfers. By invisibly placing identification codes on computers that visit its clients' Web sites, Pharmatrak Inc. can record consumers' activity when they alight on thousands of pages maintained by 11 pharmaceutical companies.
July 8, 2000 |
Vice President Al Gore reached out to female voters on Friday, continuing his attacks on big drug companies and charging that "price-gouging" and industry efforts to extend patents on expensive medications disproportionately hurt women. In a speech at a Pittsburgh-area senior center, the presumed Democratic presidential nominee stuck with the theme of the week, casting himself once again as a "champion" of the people.
March 22, 2012 |
Watching Alzheimer's disease steal away the memory, talents and very selves of its victims is hard enough for the people who love them. Now, a new pill formulated by a respected pharmaceutical company and approved by the Food and Drug Administration will do little to help most patients and will bring misery to some, say two medical investigators. The drug, Aricept 23 mg, is no more effective on the whole than the disappointing ones already on the market - but is more likely to cause gastrointestinal problems, wrote Drs. Steven Woloshin and Lisa Schwartz of Dartmouth Medical College in an article published Thursday in the medical journal BMJ. The new formulation was devised to serve commercial objectives, they say, and was approved despite a poor showing in company-sponsored tests.